SCHEMBL2938701

SCHEMBL2938701

Nc1nc(CNC2CC2)c2[nH]cnc2n1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 14/20 0.49
CDK1 P06493 14/20 0.49
CCNB1 P14635 13/20 0.49
CCNA2 P20248 13/20 0.49
CCNA1 P78396 13/20 0.49
PDPK1 O15530 1/20 0.49
GDA Q9Y2T3 1/20 0.49
MAP3K5 Q99683 2/20 0.47
PIN1 Q13526 2/20 0.47
CCNB2 O95067 1/20 0.47
MAPK3 P27361 1/20 0.47
CLK1 P49759 1/20 0.47
CDK5 Q00535 1/20 0.47
CCNB3 Q8WWL7 1/20 0.47
DPP4 P27487 1/20 0.46
MGMT P16455 5/20 0.45
HRH4 Q9H3N8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2938700 0.78 GHSR (0.35) CDK2CDK1CCNB1CCNA2CCNA1
SCHEMBL9683225 0.78 CDK2 (0.55) CDK2CDK1CCNB1CCNA2CCNA1
SCHEMBL27870406 0.75 PDPK1 (0.61) CDK2CDK1CCNB1CCNA2CCNA1
SCHEMBL133157 0.75 LMNA (0.54) CDK2CDK1PDPK1GDADPP4
SCHEMBL31642104 0.73 PDPK1 (0.59) CDK2CDK1CCNB1CCNA2CCNA1
SCHEMBL29720347 0.73 MAP3K5 (0.60) CDK2CDK1CCNB1CCNA2CCNA1
SCHEMBL7668710 0.71 PDPK1 (0.56) CDK2CDK1CCNB1CCNA2CCNA1
SCHEMBL7626878 0.70 LMNA (0.58) CDK2CDK1CCNB1CCNA2CCNA1
SCHEMBL2027219 0.70 CDK2 (0.50) CDK2CDK1CCNB1CCNA2CCNA1
SCHEMBL7621600 0.70 LMNA (0.62) CDK2CDK1CCNB1CCNA2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118931997-A Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis 上海飞腾医药科技有限公司 2024-11-12 CN claimed
CN-118931997-A Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis 上海飞腾医药科技有限公司 2024-11-12 CN disclosed
EP-1925675-B1 Process for production of nucleoside compound MITSUI CHEMICALS INC (JP) 2010-02-03 EP disclosed
EP-1338654-B1 PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND MITSUI CHEMICALS INC (JP) 2008-10-15 EP disclosed
US-7381820-B2 α-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2′-deoxy-2′-fluoro-β-d-arabinonucleoside YAMASA CORPORATION (JP) 2008-06-03 US disclosed
EP-1178051-B1 PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE MITSUI CHEMICALS INC (JP) 2008-05-28 EP disclosed
EP-1925675-A1 Process for production of nucleoside compound Mitsui Chemicals, Inc. (JP) 2008-05-28 EP disclosed
US-20070135627-A1 Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside KOHEL YAMADA, ETAL 2007-06-14 US disclosed
EP-1676853-A1 ALPHA-1-PHOSPHORYLATED-2-DEOXY-2-FLUOROARABINOSIDE AND PROCESS FOR PRODUCING 2 -DEOXY-2 -FLUORO-BETA-D-ARABINONUCLEOSID E YAMASA CORPORATION (JP) 2006-07-05 EP disclosed
US-20060094869-A1 Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside MITSUI CHEMICALS, INC. (JP) 2006-05-04 US disclosed
EP-1179598-A1 PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND Mitsui Chemicals, Inc. (JP) 2002-02-13 EP disclosed
EP-1178051-A2 PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE Mitsui Chemicals, Inc. (JP) 2002-02-06 EP disclosed
EP-1177201-A1 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES YAMASA CORPORATION (JP) 2002-02-06 EP disclosed
EP-1177202-A1 4'-C-ETHYNYL PURINE NUCLEOSIDES YAMASA CORPORATION (JP) 2002-02-06 EP disclosed
US-6333315-B1 FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-12-25 US disclosed
US-6291670-B1 VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) YAMASA CORPORATION (JP) 2001-09-18 US disclosed
WO-2000069877-A1 4'-C-ETHYNYL PURINE NUCLEOSIDES YAMASA CORPORATION (JP) 2000-11-23 WO disclosed
WO-2000069876-A1 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES YAMASA CORPORATION (JP) 2000-11-23 WO disclosed
US-6103707-A TREATMENT OF HERPES SIMPLEX VIRUS 1 (HSV-1), HERPES SIMPLEX VIRUS 2 (HSV-2), HUMAN CYTOMEGALOVIRUS (HCMV) AND VARICELLA-ZOSTER VIRUS YAMASA CORPORATION (JP) 2000-08-15 US disclosed
EP-0839813-A1 9-(2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOSYL)PURINE DERIVATIVES YAMASA CORPORATION (JP) 1998-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094869-A1 Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside PNP, MTAP, GALE CDK2 760/4885CDK1 395/4885CCNB1 1813/4885
US-20070135627-A1 Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside TYMP, PNP, DUT CDK2 157/4885CDK1 305/4885CCNB1 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.